Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post‐induction consolidation therapy

Overview of attention for article published in American Journal of Hematology, November 2016

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (54th percentile)

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 11,553 followers.

Karyotype plus NPM1 Mutation Status Defines a Group of Elderly Patients w/ AML (≥60 Years) @MedUni_Wien @univienna https://t.co/BfhqXzQ2EJ

RT @CancerPapers: Karyotype plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML… https://t.co/CJzssKyHST #leukemia https…

Karyotype plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML… https://t.co/CJzssKyHST #leukemia https://t.co/Yh1xf20EDG

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.